Inovio Pharmaceuticals, Inc.
) recently announced encouraging data from a phase I study on its
influenza vaccine candidate, SynCon. SynCon is being developed as
a universal H1N1 vaccine to protect against several prevalent
H1N1 influenza strains.
The phase I study, which enrolled 100 healthy volunteers,
evaluated SynCon in multiple dosages and constructs. It was found
that 60% of the volunteers who received the highest dose (1.8 mg)
of SynCon at least twice showed similar response rates to that of
a currently approved seasonal influenza vaccine against a
currently circulating H1N1 A/California/07/09 strain.
SynCon has demonstrated encouraging efficacy against several
vaccine strains prevalent in the last 100 years including H1N1
A/South Carolina/1/18 strain (so-called 1918 Spanish flu) as well
as all the H1N1 strains that were part of the seasonal trivalent
inactivated flu vaccines (TIV) since 1986, including,
A/Taiwan/1/86, A/Texas/36/91, A/Bayern/07/95, A/Beijing/262/95,
A/New Caledonia/20/99, A/Solomon Islands/03/06, A/Brisbane/59/07,
We believe if successfully developed and eventually approved
SynCon will revolutionize the influenza vaccine market. Currently
approved influenza vaccines include
) FluMist Quadrivalent and
) Fluarix Quadrivalent. The currently approved quadrivalent
vaccines protect from two strains of influenza A and influenza B
Inovio Pharma is also developing vaccines targeting the lucrative
pandemic influenza subtypes, H5N1 and H7N9. These vaccines are
primarily sold to government buyers.
Inovio Pharma, a biopharmaceutical company, carries a Zacks Rank
#1 (Strong Buy). Biopharma stocks like
) appear to be equally attractive. UCB also carries a Zacks Rank
ASTRAZENECA PLC (AZN): Free Stock Analysis
GLAXOSMITHKLINE (GSK): Free Stock Analysis
INOVIO PHARMAC (INO): Free Stock Analysis
UCB SA (UCBJF): Get Free Report
To read this article on Zacks.com click here.